HRP20090640T1 - Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida - Google Patents

Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida Download PDF

Info

Publication number: HRP20090640T1
Authority: HR; Croatia
Prior art keywords: hemihydrate; disorder; compound according; preparation; disorders
Prior art date: 2004-12-21

Application number

HR20090640T

Other languages

English (en)

Croatian (hr)

Inventor

Kumar Agarwal Rajesh

L. Betts William Iii

A. Henshilwood James

Kiang Yuan-Hon

Post Noah

Original Assignee

Arena Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-21

Filing date

2005-12-20

Publication date

2010-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090640(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-20 Application filed by Arena Pharmaceuticals filed Critical Arena Pharmaceuticals

2010-01-31 Publication of HRP20090640T1 publication Critical patent/HRP20090640T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

HR20090640T 2004-12-21 2005-12-20 Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida HRP20090640T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63822104P	2004-12-21	2004-12-21
PCT/US2005/046983 WO2006069363A2 (en)	2004-12-21	2005-12-20	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride

Publications (1)

Publication Number	Publication Date
HRP20090640T1 true HRP20090640T1 (hr)	2010-01-31

Family

ID=36602366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20090640T HRP20090640T1 (hr)	2004-12-21	2005-12-20	Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida

Country Status (28)

Country	Link
US (4)	US8168624B2 (pt)
EP (3)	EP2149562A1 (pt)
JP (3)	JP5270167B2 (pt)
KR (1)	KR101281919B1 (pt)
CN (2)	CN101084193B (pt)
AT (1)	ATE442359T1 (pt)
AU (1)	AU2005318959B2 (pt)
BR (1)	BRPI0519726B8 (pt)
CA (1)	CA2589988C (pt)
CU (1)	CU20070138A7 (pt)
CY (1)	CY1109599T1 (pt)
DE (1)	DE602005016603D1 (pt)
DK (1)	DK1838677T3 (pt)
EA (2)	EA201200954A1 (pt)
ES (1)	ES2332009T3 (pt)
HR (1)	HRP20090640T1 (pt)
IL (1)	IL183844A (pt)
MA (1)	MA29147B1 (pt)
ME (1)	ME01090B (pt)
NI (1)	NI200700160A (pt)
NZ (2)	NZ555981A (pt)
PL (1)	PL1838677T3 (pt)
PT (1)	PT1838677E (pt)
RS (1)	RS50996B (pt)
SI (1)	SI1838677T1 (pt)
TN (1)	TNSN07235A1 (pt)
WO (1)	WO2006069363A2 (pt)
ZA (1)	ZA200705125B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
US7704993B2 (en)	2003-06-17	2010-04-27	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
MXPA05013364A (es)	2003-06-17	2006-03-17	Arena Pharm Inc	Procedimiento para preparar 3-benzazepinas.
BRPI0519726B8 (pt)	2004-12-21	2021-05-25	Arena Pharm Inc	composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos
BRPI0515862A2 (pt)	2004-12-23	2011-10-11	Arena Pharm Inc	uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas
ES2328520T3 (es)	2005-09-01	2009-11-13	Eli Lilly And Company	2,3,4,5-tetrahidro-1h-benzo(d)azepinas 6-sustituidas como agonistas del receptor de 5-ht2c.
US20080269196A1 (en)	2005-09-01	2008-10-30	Karin Briner	6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
CA2619450C (en)	2005-09-01	2013-10-22	Eli Lilly And Company	6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP5237810B2 (ja)	2005-09-01	2013-07-17	イーライリリーアンドカンパニー	５−ＨＴ２Ｃ受容体アゴニストとしての６−置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
JP5199997B2 (ja)	2006-04-03	2013-05-15	アリーナファーマシューティカルズ，インコーポレイテッド	８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
US7897595B2 (en)	2006-05-26	2011-03-01	Forest Laboratories Holdings Limited	Pyridoazepine derivatives
JP5404414B2 (ja)	2006-12-05	2014-01-29	アリーナファーマシューティカルズ，インコーポレイテッド	（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法
US8822727B2 (en)	2008-03-04	2014-09-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2010148207A2 (en)	2009-06-18	2010-12-23	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-ht2c receptor agonists
KR20130112848A (ko)	2010-06-02	2013-10-14	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
EP2611781A1 (en) *	2010-09-01	2013-07-10	Arena Pharmaceuticals, Inc.	Fast-dissolve dosage forms of 5-ht2c agonists
SG188361A1 (en) *	2010-09-01	2013-04-30	Arena Pharm Inc	Non-hygroscopic salts of 5-ht2c agonists
KR20130138770A (ko)	2010-09-01	2013-12-19	아레나 파마슈티칼스, 인크.	광학적으로 활성 산을 갖는 로르카세린의 염
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
AU2015268758B2 (en) *	2010-09-01	2017-08-24	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-HT2c agonists useful for weight management
EP3485878A1 (en) *	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-ht2c agonists useful for weight management
US8999970B2 (en)	2010-09-01	2015-04-07	Arena Pharmaceuticals, Inc.	Administration of an anti-obesity compound to individuals with renal impairment
CA2886875A1 (en) *	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management
EP2868656A1 (en)	2013-11-05	2015-05-06	LEK Pharmaceuticals d.d.	Stabilized amorphous lorcaserin hydrochloride
US9714225B2 (en) *	2013-11-13	2017-07-25	Cadila Healthcare Limited	Processes for the preparation of lorcaserin
CN104936947B (zh) *	2013-12-27	2017-03-08	杭州普晒医药科技有限公司	氯卡色林盐及其晶体、其制备方法和用途
EP2924024A3 (en)	2014-03-21	2016-01-20	Medichem, S.A.	Solid forms of lorcaserin hydrochloride
CN105228986B (zh) *	2014-04-21	2017-11-07	杭州普晒医药科技有限公司	一种氯卡色林共晶及其制备方法、药物组合物和用途
WO2015170346A1 (en)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	A process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine its enantiomers
WO2016069875A1 (en)	2014-10-30	2016-05-06	Arena Pharmaceuticals, Inc.	Compositions and methods for ceasing tobacco smoking
CN104844512B (zh) *	2015-05-15	2017-03-29	东北制药集团股份有限公司	一种绿卡色林盐酸盐半水合物晶型的制备方法
CN104829532A (zh) *	2015-05-15	2015-08-12	浙江理工大学	一种制备绿卡色林盐酸盐单晶的方法
NO346258B1 (en) *	2015-06-30	2022-05-16	Neurad Ltd	Novel breathing control modulating compounds, and methods of making and using same
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
EP3210975A1 (en)	2016-02-24	2017-08-30	Enantia, S.L.	Cocrystals of lorcaserin
CN106478506B (zh) *	2016-09-30	2019-03-15	山东科兴生物制品有限公司	半水绿卡色林盐酸盐的制备方法
CN112704670B (zh) *	2021-01-08	2022-07-15	安徽中医药大学	一种盐酸氯卡色林渗透泵控释制剂及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH481110A (de)	1967-02-17	1969-11-15	Geigy Ag J R	Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH498122A (de)	1968-02-09	1970-10-31	Geigy Ag J R	Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
CH500194A (de)	1968-02-15	1970-12-15	Ciba Geigy Ag	Verfahren zur Herstellung von Tetrahydroazepinderivaten
GB1268243A (en)	1968-03-11	1972-03-22	Wallace & Tiernan Inc	0,2,4,5,-tetrahydro-3h,3-benzazepines
US4233217A (en)	1968-03-11	1980-11-11	Pennwalt Corporation	Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
FR7736M (pt)	1968-09-02	1970-03-09
US3716639A (en)	1970-03-11	1973-02-13	Ciba Geigy Corp	Anorexigenic tetrahydrobenzazepines
US3795683A (en)	1970-08-19	1974-03-05	Hoffmann La Roche	2,3,4,5-tetrahydro-1h-3-benzazepines
LU65954A1 (pt)	1972-08-25	1974-03-07
US4210749A (en)	1974-11-12	1980-07-01	Pennwalt Corporation	Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4111957A (en)	1977-02-02	1978-09-05	Smithkline Corporation	Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4108989A (en)	1977-04-01	1978-08-22	Smithkline Corporation	2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones
CA1090797A (en)	1978-06-20	1980-12-02	Kenneth G. Holden	Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds
AU515236B2 (en)	1978-06-26	1981-03-26	Smithkline Corporation	Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA792785B (en)	1978-07-07	1980-08-27	Smithkline Corp	Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
EP0080779B1 (en)	1981-11-27	1986-07-16	Smithkline Beckman Corporation	3-benzazepines as alpha-2 antagonists
FR2525603A1 (fr)	1982-04-27	1983-10-28	Adir	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4988690A (en)	1982-06-14	1991-01-29	Hoechst-Roussel Pharmaceuticals Inc.	1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
US4541954A (en)	1984-09-05	1985-09-17	Smithkline Beckman Corporation	Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4762845A (en)	1986-05-21	1988-08-09	Abbott Laboratories	7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
EP0285287A3 (en)	1987-03-23	1990-08-16	Smithkline Beecham Corporation	3-benzazepine compounds for use in treating gastrointestinal motility disorders
US5015639A (en)	1987-03-27	1991-05-14	Schering Corporation	Substituted benzazepines, their preparation and pharmaceutical compositions containing them
ZA882080B (en)	1987-03-27	1989-04-26	Schering Corp	Substituted benzazepines,their preparation and pharmaceutical compositions containing them
AU1700688A (en)	1987-04-09	1988-11-04	Smithkline Beckman Corporation	Sulfinyl and sulfonyl substituted 3-benzazepines
US5422355A (en)	1989-06-02	1995-06-06	John Wyeth & Brother, Limited	Composition for treating depression with (N-heteroaryl)alkylamines
US5178786A (en)	1989-08-04	1993-01-12	The Lubrizol Corporation	Corrosion-inhibiting compositions and functional fluids containing same
ZA914536B (en)	1990-06-15	1992-03-25	Schering Corp	8-lower alkyl-5-cycloalkyl or 5-cycloakenyl substituted benzazepines and pharmaceutical compositions containing them
US5275915A (en)	1991-06-05	1994-01-04	Dainippon Ink And Chemicals, Inc.	Developer for light-sensitive material
CA2110575A1 (en)	1991-06-21	1993-01-07	John Gerard Ward	Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
EP0558824A1 (en)	1992-02-04	1993-09-08	Duphar International Research B.V	Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof
JPH05339263A (ja)	1992-06-08	1993-12-21	Wakunaga Pharmaceut Co Ltd	ジヒドロピリジン誘導体
JPH06298746A (ja)	1993-04-19	1994-10-25	Showa Denko Kk	環状イミド酸エステルの製造法
US6087346A (en)	1993-06-23	2000-07-11	Cambridge Neuroscience, Inc.	Sigma receptor ligands and the use thereof
US5387685A (en)	1993-07-16	1995-02-07	American Cyanamid Co	MDR reversal agents
GB9322976D0 (en)	1993-11-08	1994-01-05	Pfizer Ltd	Therapeutic agents
DE4419315A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419246A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419247A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4427838A1 (de)	1994-08-05	1996-02-08	Thomae Gmbh Dr K	Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de)	1994-08-17	1996-02-22	Thomae Gmbh Dr K	Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08134048A (ja)	1994-11-08	1996-05-28	Sumitomo Chem Co Ltd	オキサゾリン類の製造法
GB9508622D0 (en)	1995-04-28	1995-06-14	Pfizer Ltd	Therapeutic agants
JPH0930960A (ja)	1995-07-18	1997-02-04	Takasago Internatl Corp	真菌感染症治療剤
JPH0987258A (ja)	1995-09-28	1997-03-31	Sumitomo Chem Co Ltd	オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法
CA2190708A1 (en)	1995-12-08	1997-06-09	Johannes Aebi	Aminoalkyl substituted benzo-heterocyclic compounds
US5892116A (en)	1996-01-03	1999-04-06	Georgetown University	Gelators
US5925651A (en)	1996-04-03	1999-07-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5691362A (en)	1996-06-05	1997-11-25	Schering-Plough Corporation	Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
EP0920417A4 (en)	1996-08-15	1999-12-29	Smithkline Beecham Corp	IL-8 RECEPTOR ANTAGONISTS
EP0973778A1 (en)	1997-03-07	2000-01-26	Novo Nordisk A/S	4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
AUPP020297A0 (en)	1997-11-05	1997-11-27	University Of Melbourne, The	A novel receptor, and compounds which bind thereto
EP0987235B1 (en)	1998-08-25	2003-03-12	MERCK PATENT GmbH	Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts
DE60006618T2 (de)	1999-08-06	2004-09-23	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
EP1074549B1 (en)	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
DE10003708A1 (de)	2000-01-28	2001-08-02	Solvent Innovation Gmbh	Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form
CN1254474C (zh)	2000-11-14	2006-05-03	史密斯克莱·比奇曼公司	作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
GB0030710D0 (en)	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
WO2002074746A1 (en)	2001-03-16	2002-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Benzazepine derivatives
DE10119278C1 (de)	2001-04-20	2002-10-02	Merck Patent Gmbh	Verfahren zur Herstellung von Fluoralkylphosphaten
US6825198B2 (en)	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
BR0212787A (pt)	2001-09-24	2005-01-25	Elan Pharm Inc	Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
JP2005519915A (ja)	2002-01-18	2005-07-07	セレテック・リミテッド・ライアビリティ・カンパニー	Ｅｄｇ受容体に関連する症状の処置方法
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US6953787B2 (en) *	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
GB0224557D0 (en)	2002-10-22	2002-11-27	Glaxo Group Ltd	Novel compounds
MXPA05013364A (es)	2003-06-17	2006-03-17	Arena Pharm Inc	Procedimiento para preparar 3-benzazepinas.
US7704993B2 (en)	2003-06-17	2010-04-27	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
US20070275949A1 (en)	2003-10-22	2007-11-29	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
US20080009478A1 (en)	2003-10-22	2008-01-10	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
MX2007001337A (es)	2004-08-02	2008-03-13	Genmedica Therapeutics Sl	Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
US8178077B2 (en)	2004-10-19	2012-05-15	Reverse Proteomics Research Institute Co., Ltd.	Drug development target protein and target gene, and method of screening
BRPI0519726B8 (pt)	2004-12-21	2021-05-25	Arena Pharm Inc	composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos
BRPI0515862A2 (pt)	2004-12-23	2011-10-11	Arena Pharm Inc	uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas
JP5199997B2 (ja)	2006-04-03	2013-05-15	アリーナファーマシューティカルズ，インコーポレイテッド	８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
JP5339263B2 (ja)	2007-07-26	2013-11-13	コクヨ株式会社	引き戸の取付構造、引き戸及び収納装置

2005
- 2005-12-20 BR BRPI0519726A patent/BRPI0519726B8/pt active IP Right Grant
- 2005-12-20 CN CN2005800433929A patent/CN101084193B/zh not_active Expired - Lifetime
- 2005-12-20 SI SI200530839T patent/SI1838677T1/sl unknown
- 2005-12-20 HR HR20090640T patent/HRP20090640T1/hr unknown
- 2005-12-20 EA EA201200954A patent/EA201200954A1/ru unknown
- 2005-12-20 KR KR1020077016727A patent/KR101281919B1/ko not_active Expired - Fee Related
- 2005-12-20 NZ NZ555981A patent/NZ555981A/en not_active IP Right Cessation
- 2005-12-20 CN CN2011103046342A patent/CN102321023A/zh active Pending
- 2005-12-20 WO PCT/US2005/046983 patent/WO2006069363A2/en not_active Ceased
- 2005-12-20 EP EP09011453A patent/EP2149562A1/en not_active Withdrawn
- 2005-12-20 DE DE602005016603T patent/DE602005016603D1/de not_active Expired - Lifetime
- 2005-12-20 CA CA2589988A patent/CA2589988C/en not_active Expired - Lifetime
- 2005-12-20 PL PL05855526T patent/PL1838677T3/pl unknown
- 2005-12-20 ES ES05855526T patent/ES2332009T3/es not_active Expired - Lifetime
- 2005-12-20 JP JP2007547060A patent/JP5270167B2/ja not_active Expired - Fee Related
- 2005-12-20 AU AU2005318959A patent/AU2005318959B2/en not_active Expired
- 2005-12-20 US US11/793,473 patent/US8168624B2/en active Active
- 2005-12-20 RS RSP-2009/0476A patent/RS50996B/sr unknown
- 2005-12-20 EP EP10010048.6A patent/EP2327698B1/en not_active Expired - Lifetime
- 2005-12-20 AT AT05855526T patent/ATE442359T1/de active
- 2005-12-20 EA EA200701358A patent/EA017894B1/ru unknown
- 2005-12-20 EP EP05855526A patent/EP1838677B1/en not_active Expired - Lifetime
- 2005-12-20 ME MEP-2009-338A patent/ME01090B/me unknown
- 2005-12-20 DK DK05855526T patent/DK1838677T3/da active
- 2005-12-20 PT PT05855526T patent/PT1838677E/pt unknown
- 2005-12-20 NZ NZ589756A patent/NZ589756A/en not_active IP Right Cessation
2007
- 2007-06-11 IL IL183844A patent/IL183844A/en active IP Right Grant
- 2007-06-15 CU CU20070138A patent/CU20070138A7/es unknown
- 2007-06-20 ZA ZA2007/05125A patent/ZA200705125B/en unknown
- 2007-06-20 TN TNP2007000235A patent/TNSN07235A1/fr unknown
- 2007-06-21 NI NI200700160A patent/NI200700160A/es unknown
- 2007-07-12 MA MA30070A patent/MA29147B1/fr unknown
2009
- 2009-11-10 CY CY20091101162T patent/CY1109599T1/el unknown
2012
- 2012-03-21 US US13/425,669 patent/US8697686B2/en not_active Expired - Lifetime
- 2012-05-18 JP JP2012114460A patent/JP5781008B2/ja not_active Expired - Fee Related
- 2012-09-14 US US13/616,887 patent/US8980881B2/en not_active Expired - Lifetime
2014
- 2014-06-02 JP JP2014113743A patent/JP2014156490A/ja active Pending
2015
- 2015-03-02 US US14/635,146 patent/US20160009654A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2149562A1 (en)	2010-02-03
HK1157334A1 (en)	2012-06-29
AU2005318959A1 (en)	2006-06-29
KR20070098870A (ko)	2007-10-05
IL183844A (en)	2013-11-28
CA2589988A1 (en)	2006-06-29
EP1838677A2 (en)	2007-10-03
ZA200705125B (en)	2011-07-27
NI200700160A (es)	2008-04-21
ES2332009T3 (es)	2010-01-22
RS50996B (sr)	2010-10-31
JP2008524262A (ja)	2008-07-10
CU20070138A7 (es)	2010-01-22
CY1109599T1 (el)	2014-08-13
PL1838677T3 (pl)	2010-02-26
WO2006069363A2 (en)	2006-06-29
BRPI0519726B8 (pt)	2021-05-25
EA017894B1 (ru)	2013-04-30
KR101281919B1 (ko)	2013-07-03
BRPI0519726A2 (pt)	2009-03-10
CN101084193A (zh)	2007-12-05
NZ589756A (en)	2012-05-25
SI1838677T1 (sl)	2010-01-29
US20120264743A1 (en)	2012-10-18
ME01090B (me)	2012-12-20
US20140051684A1 (en)	2014-02-20
EA201200954A1 (ru)	2013-05-30
ATE442359T1 (de)	2009-09-15
EA200701358A1 (ru)	2007-12-28
CN102321023A (zh)	2012-01-18
JP2012153727A (ja)	2012-08-16
WO2006069363A3 (en)	2007-05-10
HK1102812A1 (en)	2007-12-07
JP2014156490A (ja)	2014-08-28
PT1838677E (pt)	2009-11-16
EP2327698B1 (en)	2015-08-05
US8168624B2 (en)	2012-05-01
BRPI0519726B1 (pt)	2020-11-24
DK1838677T3 (da)	2010-01-11
JP5781008B2 (ja)	2015-09-16
MA29147B1 (fr)	2008-01-02
DE602005016603D1 (de)	2009-10-22
EP1838677B1 (en)	2009-09-09
US8980881B2 (en)	2015-03-17
CN101084193B (zh)	2011-12-07
CA2589988C (en)	2017-02-14
AU2005318959B2 (en)	2011-12-15
NZ555981A (en)	2011-01-28
US8697686B2 (en)	2014-04-15
EP2327698A1 (en)	2011-06-01
US20100004223A1 (en)	2010-01-07
IL183844A0 (en)	2007-10-31
US20160009654A1 (en)	2016-01-14
TNSN07235A1 (en)	2008-11-21
JP5270167B2 (ja)	2013-08-21

Publication	Publication Date	Title
JP2008524262A5 (pt)	2009-02-05
ME01090B (me)	2012-12-20	Kristalni oblici (r)-8-hloro-metil-2,3,4,5-tetrahidr0-1h-3-benzazepin hlorhidrat
RU2018130727A (ru)	2020-02-27	Органические соединения
JP2013512926A5 (pt)	2014-01-23
JP2004519438A5 (pt)	2005-05-26
JP2007516941A5 (pt)	2007-08-09
JP2005521671A5 (pt)	2005-12-22
JP2002523491A5 (pt)	2006-11-02
CA2529320A1 (en)	2005-01-13	Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
AR059183A1 (es)	2008-03-12	Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos
JP2002523506A5 (pt)	2006-11-02
MX2009013742A (es)	2010-01-26	2-imidazolinas.
TW200833685A (en)	2008-08-16	Aminomethyl-4-imidazoles
JP2015521642A5 (pt)	2016-08-12
MX2009005509A (es)	2009-06-03	2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
JP2011518858A5 (pt)	2012-06-14
JP2002525280A5 (pt)	2006-10-26
MX2010009643A (es)	2010-09-22	Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
JP2014518552A5 (pt)	2015-04-16
JP2015521643A5 (pt)	2016-08-12
EA200801488A1 (ru)	2010-02-26	Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью
JP2008526706A5 (pt)	2009-02-19
JP2008523075A5 (pt)	2009-01-22
JP2012526775A5 (pt)	2015-06-25
MX2010009403A (es)	2010-09-24	Derivados de 2-aminoquinolina.